Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse.
biomarker
clinical trial
relapse
tuberclosis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 02 2023
08 02 2023
Historique:
received:
13
12
2021
pubmed:
20
6
2022
medline:
11
2
2023
entrez:
19
6
2022
Statut:
ppublish
Résumé
Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 weeks of treatment; MGIT TTP showed a significant difference from week 8.
Identifiants
pubmed: 35717643
pii: 6611480
doi: 10.1093/cid/ciac445
pmc: PMC9907486
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e990-e994Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. N. E. N., D. M., W. S., G. K., L. T. M., D. K., K. R., P. P. J. P., M. J. B., S. H. G., M. H., and N. H. report an EDCTP grant through the PanACEA Consortium. Additionally, S. H. G. received a UK Medical Research Council grant through his institution, and N. H. has received a research grant from Beckman Coulter and equipment from Cepheid, as research support to his institution. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79
pubmed: 10529902
Int J Tuberc Lung Dis. 2012 Apr;16(4):455-61
pubmed: 22640511
Methods Mol Biol. 2017;1616:89-105
pubmed: 28600763
J Clin Microbiol. 2014 Aug;52(8):3064-7
pubmed: 24871215
Thorax. 2020 Jul;75(7):606-608
pubmed: 32354738
Nat Med. 2016 Oct;22(10):1094-1100
pubmed: 27595324
J Clin Microbiol. 2011 Nov;49(11):3905-11
pubmed: 21900522
Nat Med. 2018 Nov;24(11):1708-1715
pubmed: 30397355
Lancet Infect Dis. 2017 Jan;17(1):39-49
pubmed: 28100438
Front Microbiol. 2015 Jun 23;6:641
pubmed: 26157437
J Infect Dis. 2012 May 15;205 Suppl 2:S250-7
pubmed: 22448027